These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11273232)

  • 1. Failure of postexposure prophylaxis after sexual exposure to HIV.
    Fournier S; Maillard A; Molina JM
    AIDS; 2001 Feb; 15(3):430. PubMed ID: 11273232
    [No Abstract]   [Full Text] [Related]  

  • 2. Onset of HIV-1 antibody production after highly active antiretroviral therapy in a seronegative HIV-1-infected child.
    De Rossi A; Giaquinto C; Del Mistro A; Zamarchi R; Chieco-Bianchi L
    AIDS; 2000 Jun; 14(9):1284-6. PubMed ID: 10894299
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
    Rabaud C; Bevilacqua S; Beguinot I; Dorvaux V; Schuhmacher H; May T; Canton P
    Clin Infect Dis; 2001 May; 32(10):1494-5. PubMed ID: 11317252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
    Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis.
    Katzenstein TL; Dickmeiss E; Aladdin H; Hede A; Nielsen C; Nielsen H; Jørgensen LB; Gerstoft J
    Ann Intern Med; 2000 Jul; 133(1):31-4. PubMed ID: 10877737
    [No Abstract]   [Full Text] [Related]  

  • 7. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
    Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
    Ferrer E; Podzamczer D; Arnedo M; Fumero E; McKenna P; Rinehart A; Pérez JL; Barberá MJ; Pumarola T; Gatell JM; Gudiol F;
    J Infect Dis; 2003 Feb; 187(4):687-90. PubMed ID: 12599088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion.
    Smith DE; Kaufmann GR; Kahn JO; Hecht FM; Grey PA; Zaunders JJ; Cunningham PH; Carr A; Duncombe C; Quan DC; Petersen A; Cooper DA
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):189-99. PubMed ID: 12689411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
    Nerad JL; Kessler HA
    Clin Infect Dis; 2001 Jun; 32(11):1635-6. PubMed ID: 11340537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
    Havlir DV; Marschner IC; Hirsch MS; Collier AC; Tebas P; Bassett RL; Ioannidis JP; Holohan MK; Leavitt R; Boone G; Richman DD
    N Engl J Med; 1998 Oct; 339(18):1261-8. PubMed ID: 9791141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
    Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
    N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).
    Saag MS; Tebas P; Sension M; Conant M; Myers R; Chapman SK; Anderson R; Clendeninn N;
    AIDS; 2001 Oct; 15(15):1971-8. PubMed ID: 11600825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
    Moolasart P; Likanonsakul S
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
    Winston A; McAllister J; Amin J; Cooper DA; Carr A
    HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV effects of nelfinavir reported after ten months of combination therapy.
    AIDS Patient Care STDS; 1997 Aug; 11(4):289-90. PubMed ID: 11361848
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prophylactic antiretroviral therapy after sexual exposure to HIV: 93 cases].
    Timsit FJ; Maillard A; Spindler E; Taquin Y; Deniaud F; Ferchal F; Morel P; Janier M
    Ann Dermatol Venereol; 2002; 129(6-7):866-9. PubMed ID: 12218913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
    Kahn JO; Martin JN; Roland ME; Bamberger JD; Chesney M; Chambers D; Franses K; Coates TJ; Katz MH
    J Infect Dis; 2001 Mar; 183(5):707-14. PubMed ID: 11181146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.